Lucas Ian Veloso Correia

Lucas Ian Veloso Correia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucas Ian Veloso Correia has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A New Approach to Inhibiting Triple-Negative Breast Cancer: In Vitro, Ex Vivo and In Vivo Antiangiogenic Effect of BthTx-II, a PLA2-Asp-49 from Bothrops jararacussu Venom

    by Fernanda Van Petten de Vasconcelos Azevedo, Daiana Silva Lopes, Mariana Alves Pereira Zóia, Lucas Ian Veloso Correia, Natieli Saito, Belchiolina Beatriz Fonseca, Lorena Polloni, Samuel Cota Teixeira, Luiz Ricardo Goulart, Veridiana de Melo Rodrigues Ávila

    Phospholipases A2 (PLA2) represent a superfamily of enzymes widely distributed in living organisms, with a broad spectrum of pharmacological activities and therapeutic potential. Anti-angiogenic strategies have become one of the main tools in fighting cancer. In this sense, the present work reports the inhibition of tumor angiogenesis induced by Asp-49 BthTX-II using in vitro, ex vivo and in vivo approaches. We demonstrate that BthTx-II inhibited cell adhesion, proliferation, and migration of human umbilical vein endothelial cells (HUVEC), as well as caused a reduction in the levels of endothelial growth factor (VEGF) during in vitro angiogenesis assays. BthTx-II was also able to inhibit the sprouting angiogenic process, by the ex vivo germination assay of the aortic ring; in addition, this toxin inhibited the migration and proliferation of HUVEC in co-culture with triple-negative breast cancer cells (e.g., MDA-MB-231 cells). Finally, in vivo tumor suppression and anti-angiogenic activities were analyzed using MDA-MB-231 cells with Matrigel injected into the chorioallantoic membrane of chicken embryo (CAM) for 7 days treatment with BthTx-II, showing a considerable reduction in vessel caliber, on the size and weight of tumors. Together, these results suggest an important antiangiogenic and antitumor role for BthTx-II, as a potential prototype for the development of new tools and antitumor drugs in cancer therapy.


  • Open Access

    Shedding Lights on Crude Venom from Solitary Foraging Predatory Ant Ectatomma opaciventre: Initial Toxinological Investigation

    by Lucas Ian Veloso Correia, Fernanda Van Petten de Vasconcelos Azevedo, Fernanda Gobbi Amorim, Sarah Natalie Cirilo Gimenes, Lorena Polloni, Mariana Alves Pereira Zoia, Mônica Soares Costa, Jéssica Peixoto Rodrigues, Kelly A. Geraldo Yoneyama, Jean Carlos Santos, et al.

    Some species of primitive predatory ants, despite living in a colony, exercise their hunting collection strategy individually; their venom is painful, paralyzing, digestive, and lethal for their prey, yet the toxins responsible for these effects are poorly known. Ectatomma opaciventre is a previously unrecorded solitary hunting ant from the Brazilian Cerrado. To overcome this hindrance, the present study performed the in vitro enzymatic, biochemical, and biological activities of E. opaciventre to better understand the properties of this venom. Its venom showed several proteins with masses ranging from 1–116 kDa, highlighting the complexity of this venom. Compounds with high enzymatic activity were described, elucidating different enzyme classes present in the venom, with the presence of the first L-amino acid oxidase in Hymenoptera venoms being reported. Its crude venom contributes to a state of blood incoagulability, acting on primary hemostasis, inhibiting collagen-induced platelet aggregation, and operating on the fibrinolysis of loose red clots. Furthermore, the E. opaciventre venom preferentially induced cytotoxic effects on lung cancer cell lines and three different species of Leishmania. These data shed a comprehensive portrait of enzymatic components, biochemical and biological effects in vitro, opening perspectives for bio-pharmacological application of E. opaciventre venom molecules.


  • Generation and In-planta expression of a recombinant single chain antibody with broad neutralization activity on Bothrops pauloensis snake venom

    by Jessica B. Souza, Rone Cardoso, Hebréia O. Almeida-Souza, Camila P. Carvalho, Lucas Ian Veloso Correia, Paula Cristina B. Faria, Galber R. Araujo, Mirian M. Mendes, Renata Santos Rodrigues, Veridiana M. Rodrigues, et al.


  • Open Access

    Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1

    by Mariana Alves Pereira Zóia, Fernanda Van Petten Azevedo, Lara Vecchi, Sara Teixeira Soares Mota, Vinícius de Rezende Rodovalho, Antonielle Oliveira Cordeiro, Lucas Ian Veloso Correia, Anielle Christine Almeida Silva, Veridiana de Melo Rodrigues Ávila, Thaise Gonçalves de Araújo, et al.

    Triple-negative breast cancers (TNBCs) are more aggressive than other breast cancer (BC) subtypes and lack effective therapeutic options. Unraveling marker events of TNBCs may provide new directions for development of strategies for targeted TNBC therapy. Herein, we reported that Annexin A1 (AnxA1) and Cathepsin D (CatD) are highly expressed in MDA-MB-231 (TNBC lineage), compared to MCF-10A and MCF-7. Since the proposed concept was that CatD has protumorigenic activity associated with its ability to cleave AnxA1 (generating a 35.5 KDa fragment), we investigated this mechanism more deeply using the inhibitor of CatD, Pepstatin A (PepA). Fourier Transform Infrared (FTIR) spectroscopy demonstrated that PepA inhibits CatD activity by occupying its active site; the OH bond from PepA interacts with a CO bond from carboxylic acids of CatD catalytic aspartate dyad, favoring the deprotonation of Asp33 and consequently inhibiting CatD. Treatment of MDA-MB-231 cells with PepA induced apoptosis and autophagy processes while reducing the proliferation, invasion, and migration. Finally, in silico molecular docking demonstrated that the catalytic inhibition comprises Asp231 protonated and Asp33 deprotonated, proving all functional results obtained. Our findings elucidated critical CatD activity in TNBC cell trough AnxA1 cleavage, indicating the inhibition of CatD as a possible strategy for TNBC treatment.


  • Open Access

    Biocompatibility of Doped Semiconductors Nanocrystals and Nanocomposites

    by Anielle Christine Almeida Silva, Mariana Alves Pereira Zóia, Lucas Ian Veloso Correia, Fernanda Van Petten Vasconcelos Azevedo, Aline Teodoro de Paula, Larissa Prado Maia, Layara Santana de Carvalho, Loyna Nobile Carvalho, Maria Paula Camargo Costa, Layssa Carrilho Giaretta, et al.

    Exposure of humans and environment to nanocrystals are inevitable, and nanotoxicological analyses are a requirement. The wide variety of nanocrystals with different applications is increasing, and cha


  • Open Access

    Biocompatible Magic Sized Quantum Dots: Luminescent Markers and Probes

    by Anielle Christine Almeida Silva, Lucas Ian Veloso Correia, Marcelo José Barbosa Silva, Mariana Alves Pereira Zóia, Fernanda Van Petten Vasconcelos Azevedo, Jéssica Peixoto Rodrigues, Luiz Ricardo Goulart, Veridiana de Melo Ávila, Noelio Oliveira Dantas

    Nanoscience and nanobiotechnology have aroused great academic and technological interest. Works relating biomaterials at the nanoscale can reach new biotechnologies and help in the development and use